MedTrace Logo

Lignosus Rhinoceros TM02® as a Complementary Therapy for Uncontrolled Asthma

NCT06451328 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2024-06-11

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if TM02® works to treat partially controlled or uncontrolled asthma in adults. It will also learn about the efficacy and safety of TM02®.

The main questions it aims to answer are:

Does TM02® causes bronchodilation (to what extent), improves asthma control, and reduces airway inflammation and blood eosinophils and serum immunoglobulin E levels.

Participants will:

Take TM02® every day for 90 days. Visit the clinic once every 30 days for checkups, tests and to fill up questionnaires.

Keep a diary of their symptoms and the number of times they use a rescue inhaler.

Conditions

Interventions

DRUG

Lignosus rhinoceros TM02®

Lignosus rhinoceros TM02®

Sponsors & Collaborators

  • University of Malaya

    lead OTHER

Principal Investigators

  • Mau Ern Poh, MBBS · Universiti Malaya

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-02-28
Completion
2023-02-28

Countries

  • Malaysia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06451328 on ClinicalTrials.gov